Overview

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Status:
Completed
Trial end date:
2018-08-05
Target enrollment:
0
Participant gender:
Female
Summary
This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab in comparison to Herceptin® (Genentech/Roche) in patients with Human Epidermal Growth Factor Receptor 2-Positive breast cancer. The main objective is to verify the non-inferiority of AryoTrust (Aryogen trastuzumab) vs. Herceptin® (Genentech/Roche trastuzumab), both given concomitantly with docetaxel after doxorubicin plus cyclophosphamide in the neoadjuvant setting according to pathological complete response (pCR) as primary objective and objective response (cOR), clinical complete response (cCR), clinical partial response (cPR), clinical stable disease (cSD), clinical progressive disease (cPD), breast conservation rate as Secondary objectives of this study. Evaluating the safety and immunogenicity of AryoTrust vs. Herceptin®, are also the other secondary outcomes. This study has two arms and 108 subjects will participate with a 1:1 allocation and receive mentioned treatment randomly.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AryoGen Pharmed Co.
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin
Trastuzumab
Criteria
Inclusion Criteria:

- 18-70 years old female patients

- Patients with newly diagnosed stage III (locally advanced) or inoperable stage II (due
to sizes larger than 5 cm or high tumor to breast ratio) tumors are candidates for
participation.

- Willing and able to sign an informed consent

- Pathological diagnosis of adenocarcinoma of the breast

- ECOG status of 0-1

- With any ER/PR status

- HER2 positive (Immunohistochemical (IHC) 3+ intensity, amplification of the HER2 gene
on fluorescence in situ hybridization (FISH+ ) or HER2 positive results of Chromogenic
in situ hybridization (CISH+)).

Exclusion Criteria:

- Clinical or radiologic evidence of metastatic disease

- History of any other malignancy including previous breast cancer, second non-breast
malignant disease

- History of previous chemotherapy

- Left ventricular ejection fraction [LVEF] <55% confirmed by echo cardiogram within 3
months before registration, Any prior myocardial infarction, History of documented
congestive heart failure (CHF),Any prior history of arrhythmia or cardiac valvular
disease requiring medications or clinically significant, Current use of medications
for treatment of angina pectoris, Current uncontrolled hypertension (diastolic > 100
mmHg or systolic > 200 mmHg), A severe conduction abnormality (having pacemaker or
diagnosed by the ECG) and any other significant cardiovascular disease.

- Hematologic abnormalities including baseline Absolute Neutrophil Count (ANC) of
≤1,500/µL or platelet count ≤ 100,000/µL

- Liver dysfunction including : (baseline)

- Alanine amino transferase (ALT) and/or aspartate amino transferase (AST) ≥ 3
Upper Limit Normal (ULN)

- Alkaline phosphatase (ALP) ≥3 ͯ ULN

- serum total bilirubin > 1.5 ULN

- Renal dysfunction, defined as serum creatinine ≥2.5 mg/dL

- Pregnant, lactating women or women of childbearing potential who are not willing to
use adequate contraception